New epilepsy drug vormatrigine enters final testing phase

NCT ID NCT07505004

Ongoing Disease control Sponsor: Praxis Precision Medicines Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 04, 2026 · Updated 2 times

Summary

This Phase 3 trial is testing whether the experimental drug vormatrigine can reduce the frequency of focal seizures in adults with epilepsy. About 300 participants who already take 1 to 3 seizure medications will receive either a low, medium, or high dose of vormatrigine or a placebo daily for 12 weeks. The main goal is to see if vormatrigine leads to a greater reduction in monthly seizures compared to placebo.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: vormatrigine
What this could lead to: If successful, this could provide a new treatment option for adults with focal seizures that are not fully controlled by current medications.
What could go wrong: This is a Phase 3 trial, but results may not show a significant benefit over placebo. Side effects are possible, and the drug may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FOCAL EPILEPSY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

focal epilepsy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FOCAL EPILEPSY

Contacts and locations

Locations

Praxis Research Site

Miami, Florida, 33133, United States
Praxis Research Site

Miami Lakes, Florida, 33016, United States
Praxis Research Site

Naples, Florida, 34116, United States
Praxis Research Site

Marlboro, New Jersey, 07746, United States
Praxis Research Site

Niagara Falls, New York, 14304, United States
Praxis Research Site

Raleigh, North Carolina, 27607, United States
Praxis Research Site

Houston, Texas, 77058, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.